biote Corp. (NASDAQ:BTMD) Major Shareholder Guines Llc Purchases 13,532 Shares

biote Corp. (NASDAQ:BTMD) major shareholder Guines Llc bought 13,532 shares of the firm’s stock in a transaction on Wednesday, April 9th. The shares were purchased at an average price of $3.21 per share, for a total transaction of $43,437.72. Following the completion of the transaction, the insider now owns 4,156,426 shares of the company’s stock, valued at $13,342,127.46. This represents a 0.33 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Guines Llc also recently made the following trade(s):

• On Monday, April 7th, Guines Llc purchased 43,378 shares of biote stock. The shares were purchased at an average cost of $3.15 per share, with a total value of $136,640.70.
• On Thursday, April 3rd, Guines Llc acquired 7,321 shares of biote stock. The stock was acquired at an average cost of $3.24 per share, for a total transaction of $23,720.04.
• On Monday, March 31st, Guines Llc bought 106,000 shares of biote stock. The shares were acquired at an average price of $3.32 per share, with a total value of $351,920.00.
• On Monday, March 17th, Guines Llc purchased 100 shares of biote stock. The stock was acquired at an average cost of $3.74 per share, for a total transaction of $374.00.
• On Thursday, March 13th, Guines Llc acquired 750,000 shares of biote stock. The shares were acquired at an average cost of $3.22 per share, with a total value of $2,415,000.00.

biote Stock Down 4.6 %

BTMD opened at $3.35 on Friday. The firm has a market cap of $183.28 million, a P/E ratio of 12.88 and a beta of 1.17. The business’s fifty day simple moving average is $4.09 and its 200 day simple moving average is $5.20. biote Corp. has a 52 week low of $3.04 and a 52 week high of $8.44.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio purchased a new stake in shares of biote during the fourth quarter worth about $69,000. Squarepoint Ops LLC acquired a new stake in biote during the fourth quarter worth approximately $115,000. Millennium Management LLC purchased a new stake in biote in the 4th quarter worth approximately $414,000. Lazard Asset Management LLC acquired a new position in biote in the 4th quarter valued at $139,000. Finally, Deutsche Bank AG lifted its stake in shares of biote by 4,987.5% during the 4th quarter. Deutsche Bank AG now owns 31,441 shares of the company’s stock worth $194,000 after purchasing an additional 30,823 shares during the period. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Craig Hallum reduced their target price on biote from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, March 13th.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.